This pilot study will include women with stage II-IV ER/PR/HER2 negative (triple negative)
        breast cancer scheduled to undergo surgical resection.

        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Confirmation of invasive breast cancer including any of the following:

               -  Triple-negative breast cancer defined as receptor status being estrogen receptor
                  expression ≤ 10%, progesterone receptor expression ≤ 10%, and HER2/Neu expression
                  by IHC 0 or 1+, or 2+ with fluorescence in situ hybridization confirming no
                  amplification of HER2 on a pretreatment tumor sample.

               -  Hormone positive breast cancer defined as receptor status being estrogen receptor
                  expression > 10%, progesterone receptor expression > 10% prior to initiation of
                  chemotherapy.

               -  HER2+ breast cancer defined as HER2/Neu expression by IHC 3+ or fluorescence in
                  situ hybridization confirming amplification of HER2 on a pretreatment tumor
                  sample prior to initiation of chemotherapy. HER2+ and hormone positive (ie triple
                  positive) breast cancers are included in this study.

          -  Stage II-III invasive breast cancer with ≥ 1 cm of residual tumor based on MRI,
             mammogram, ultrasound, or breast clinical exam as SOC after completion of neoadjuvant
             chemotherapy, OR Stage IV BC with ≥ 1 cm locally recurrent disease (i.e. chest wall
             recurrence only)

          -  ECOG ≤ 1

          -  Hemoglobin ≥ 9.0 g/dl, ANC ≥ 1,500 cells/µl, platelets ≥ 100,000 cells/µl

          -  Women must have had last dose of chemotherapy at least 3 weeks prior to treatment with
             PVSRIPO

          -  Women must have at least 2 weeks minimum (ideal 3-4 weeks) of a wash-out period after
             any steroid administration (IV, PO, or intraocular)

          -  Serum creatinine ≤ 1.5 mg/dl, serum SGOT and bilirubin ≤ 1.5 times ULN (upper limit of
             normal)

          -  Women must provide written informed consent prior to enrollment on study, prior to
             conduct of screening procedures and enrollment on study

          -  Women of childbearing potential will have a negative serum pregnancy test at screening

          -  Women of childbearing potential must be willing to avoid pregnancy for the course of
             the study through 120 days after PVSRIPO injection

          -  Surgical resection of the tumor is planned and patient is willing to undergo surgical
             resection of the cancer

        Exclusion Criteria:

          -  T1 N0 invasive breast cancer

          -  Breast cancer with skin necrosis

          -  Concurrent immune therapy, chemotherapy, or steroid therapy

          -  Is currently participating in or has participated in a study of an investigational
             agent or using an investigational device within 4 weeks prior to polio vaccine booster

          -  Has a known diagnosis of immunodeficiency

          -  Has a known additional malignancy that is progressing or requires active treatment

          -  Has known active central nervous system metastases and/or carcinomatous meningitis

          -  Has an active autoimmune disease requiring systemic treatment within the past 3 months
             or a documented history of clinically severe autoimmune disease or a syndrome that
             requires systemic steroids or immunosuppressive agents

          -  Has an active infection requiring systemic therapy

          -  Has known psychiatric or substance abuse disorders that would interfere with the
             requirements of the trial

          -  Is pregnant, breastfeeding, or expecting to conceive children within the projected
             duration of the trial, starting with the screening visit through 120 days after trial
             treatment

          -  Has received prior therapy with an anti-PD-1, anti-PDL-1, anti-PDL-2, anti-CD137, or
             anti-CTLA-4 (or any other antibody or drug specifically targeting T cell
             co-stimulation or checkpoint pathways)

          -  Has a known history of Human Immunodeficiency Virus (HIV)

          -  Has known active Hepatitis B or Hepatitis C

          -  Active liver disease with elevated transaminases > 2x ULN

          -  Has received a live vaccine within 30 days prior to PVSRIPO treatment

               -  Inactivated vaccines are acceptable and are not an exclusion criterion